194 related articles for article (PubMed ID: 37597578)
21. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
[TBL] [Abstract][Full Text] [Related]
22. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.
Zheng Y; Shen G; Zhang C; Huo X; Xin Y; Fang Q; Guan Y; Zhao F; Ren D; Liu Z; Wang M; Zhao J
Clin Exp Med; 2023 Nov; 23(7):3205-3216. PubMed ID: 37120775
[TBL] [Abstract][Full Text] [Related]
24. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
25. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
[TBL] [Abstract][Full Text] [Related]
28. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
29. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; Ow S; Kim SB; Lin J; Chung HC; Ngan R; Kok VC; Rau KM; Sangai T; Ng TY; Tseng LM; Bryce R; Bebchuk J; Chen MC; Hou MF
Breast Cancer Res Treat; 2021 Oct; 189(3):665-676. PubMed ID: 34553296
[TBL] [Abstract][Full Text] [Related]
31. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
32. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
34. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
35. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ; Fernando TM; Bowen R; Jerzak KJ; Song X; Decker T; Boyle F; McCune S; Armstrong A; Shannon C; Bertelli G; Chang CW; Desai R; Gupta K; Wilson TR; Flechais A; Bardia A
Clin Cancer Res; 2022 Aug; 28(15):3256-3267. PubMed ID: 35583555
[TBL] [Abstract][Full Text] [Related]
36. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
37. Neratinib Efficacy and Circulating Tumor DNA Detection of
Ma CX; Bose R; Gao F; Freedman RA; Telli ML; Kimmick G; Winer E; Naughton M; Goetz MP; Russell C; Tripathy D; Cobleigh M; Forero A; Pluard TJ; Anders C; Niravath PA; Thomas S; Anderson J; Bumb C; Banks KC; Lanman RB; Bryce R; Lalani AS; Pfeifer J; Hayes DF; Pegram M; Blackwell K; Bedard PL; Al-Kateb H; Ellis MJC
Clin Cancer Res; 2017 Oct; 23(19):5687-5695. PubMed ID: 28679771
[No Abstract] [Full Text] [Related]
38. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.
Yuan Y; Lee JS; Yost SE; Stiller T; Blanchard MS; Padam S; Katheria V; Kim H; Sun C; Tang A; Martinez N; Patel ND; Sedrak MS; Waisman J; Li D; Sanani S; Presant CA; Mortimer J
J Geriatr Oncol; 2021 Jun; 12(5):752-758. PubMed ID: 33663941
[TBL] [Abstract][Full Text] [Related]
39. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Hurvitz SA; Saura C; Oliveira M; Trudeau ME; Moy B; Delaloge S; Gradishar W; Kim SB; Haley B; Ryvo L; Dai MS; Milovanov V; Alarcón J; Kalmadi S; Cronemberger E; Souza C; Landeiro L; Bose R; Bebchuk J; Kabbinavar F; Bryce R; Keyvanjah K; Brufsky AM
Oncologist; 2021 Aug; 26(8):e1327-e1338. PubMed ID: 34028126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
